tiprankstipranks
Advertisement
Advertisement
Kyntra: Advancing Oncology and LR-MDS Programs with Strong Cash Position; Buy Rating and $43 Price Target Reiterated
PremiumRatingsKyntra: Advancing Oncology and LR-MDS Programs with Strong Cash Position; Buy Rating and $43 Price Target Reiterated
1M ago
FGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
FGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
Kyntra Bio Faces Nasdaq Compliance Challenge After Revenue Shift
Premium
Company Announcements
Kyntra Bio Faces Nasdaq Compliance Challenge After Revenue Shift
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100